"

Cangrelor is a high-affinity, reversible inhibitor of P2Y12 as an antiplatelet drug. It is an active drug not requiring metabolic conversion. And It is a receptors that causes almost complete inhibition of ADP-induced platelet aggregate.

Since Cangrelor’s effects are immediate and quickly reversed, it is a more desirable drug for elective treatment of stenotic coronary arteries, high risk acute coronary syndromes treated with immediate coronary stenting, and for bridging those surgery patients who require P2Y12 inhibition.

Current evidence regarding Cangrelor therapy is limited by the lack studies assessing Cangrelor administration in conjunction with either Prasugrel or Ticagrelor.

we provide API and intermediates with non-infringing. top quanlity, more competitive price.

Special packing is offered.

"